These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33356019)

  • 1. Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study.
    Masters JC; LaBadie RR; Salageanu J; Li J; Shaik N
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):707-717. PubMed ID: 33356019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers.
    Shaik N; LaBadie RR; Hee B; Chan G
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):241-250. PubMed ID: 33388951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers.
    Shaik MN; Hee B; Wei H; LaBadie RR
    Br J Clin Pharmacol; 2018 Jun; 84(6):1346-1353. PubMed ID: 29488303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.
    Shaik N; Hee B; Wei H; LaBadie RR
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):463-472. PubMed ID: 30536154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects.
    Flanagan S; Ong V; Marbury T; Jandourek A; Gandhi RG; Sandison T
    Pharmacotherapy; 2024 Jun; 44(6):435-443. PubMed ID: 38840536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers.
    Shaik N; Hee B; Liang Y; LaBadie RR
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):895-902. PubMed ID: 30977980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
    Eley T; He B; Chang I; Colston E; Child M; Bedford W; Kandoussi H; Pasquinelli C; Marbury TC; Bertz RJ
    Antivir Ther; 2015; 20(1):29-37. PubMed ID: 24704773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies.
    Ruiz-Garcia A; Shaik N; Lin S; Jamieson C; Heuser M; Chan G
    J Clin Pharmacol; 2021 Mar; 61(3):349-359. PubMed ID: 32974950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants.
    Fan B; Dai D; Cohen M; Xu H; Yin F; Nagaraja R; Mobilia M; Almon C; Basile FG; Yang H
    Clin Pharmacol Drug Dev; 2021 Jan; 10(1):99-109. PubMed ID: 32648303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
    Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
    Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects.
    Krauwinkel W; Noukens J; van Dijk J; Popa S; Ouatas T; de Vries M; Phung D; Gibbons J; Mordenti J; Mateva L
    J Clin Pharm Ther; 2017 Jun; 42(3):268-275. PubMed ID: 28251667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
    Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
    Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.
    Giri N; Lam LH; LaBadie RR; Krzyzaniak JF; Jiang H; Hee B; Liang Y; Shaik MN
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1249-1260. PubMed ID: 29086063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment.
    Csonka D; Hazell K; Waldron E; Lorenzo S; Duval V; Trandafir L; Kobalava ZD
    J Clin Pharmacol; 2016 Mar; 56(3):316-23. PubMed ID: 26183800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open-Label, Single-Dose, Parallel Group Study.
    Song I; Chen G; Wu J; Ilic K
    J Clin Pharmacol; 2023 Feb; 63(2):250-258. PubMed ID: 36089648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study.
    Chen X; Cui X; Pognan N; Quinlan M; Kapoor S; Rahmanzadeh G; Giovannini M; Marbury TC
    Br J Clin Pharmacol; 2022 Jan; 88(1):91-102. PubMed ID: 34046915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
    Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
    Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
    Miyatake D; Shibata T; Toyoshima J; Kaneko Y; Oda K; Nishimura T; Katashima M; Sakaki M; Inoue K; Ito T; Uchida N; Furihata K; Urae A
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):699-708. PubMed ID: 31833184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone.
    Park J; Kim CO; Oh ES; Lee JI; Kim JK; Ahn SH; Kim DY; Kim SU; Kim BK; Chung YE; Kim SM; Park MS
    Clin Pharmacol Drug Dev; 2022 May; 11(5):576-584. PubMed ID: 35255191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Model-Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study.
    Masters JC; Shaik N; Mendes da Costa L; Hee B; LaBadie RR
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):272-282. PubMed ID: 32790066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.